ArticleNeoplasia (New York, N.Y.)2026
BRCA1 deficiency induces NFκB-dependent type-I interferon signaling in fallopian tube epithelial cells.
Article in Neoplasia (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BRCA1 mutation confers elevated risk for high-grade serous tubal-ovarian cancer (HGSTOC) arising from the fallopian tube epithelium (FTE) and is associated with increased proinflammatory NFκB signaling. Recent evidence indicates this signaling may be mediated by stimulation of cGAS-STING, a pattern recognition receptor (PRR), that can also activate IRF3 to drive type-I interferon (IFN-I) production and increased expression of interferon-stimulated genes. We investigated the impact of CRISPR-Cas9 generated homozygous and heterozygous disruption of BRCA1 on IFN-I signaling in FTE cells. Loss of BRCA1 associated with increased activation of IRF3, STAT2, and increased levels of IFN-I target gene transcripts and protein, including ISG15, USP18 and ISGylation. In contrast, a consistent increase in canonical or non-canonical NFκB activation or downstream target gene expression was not observed. Inhibition of TBK1, which mediates activation of IRF3 by multiple PRRs, blocked the increase in both ISG15 and USP18 whereas the increase in USP18 but not ISG15 in BRCA1-disrupted cells was partially blocked by inhibition of STING. Inhibition of NFκB activation or IFN-I signaling decreased elevated levels of IFN-I-stimulated genes with no further inhibition provided by combining inhibitors. These findings indicate that BRCA1 deficiency preferentially enhances proinflammatory IFN-I signaling in an NFκB-permissive manner and support further investigation of targeting PRR signaling in FTE cells as a potential strategy to mitigate the risk of HGSTOC in BRCA1 mutation carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.